Adropin: Physiology and What Research Reports

What adropin is

Adropin is a small secreted peptide encoded by the Energy Homeostasis Associated (ENHO) gene. In the research literature it is usually discussed as a metabolic regulator: a circulating factor whose expression tracks nutritional state and whose administration in animals has been reported to shift how tissues use fuel. Unlike insulin or glucagon, adropin is not a classical endocrine hormone with a long clinical history — it was described relatively recently, and most of what is known comes from rodent experiments, cell work and observational human measurements of serum levels.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any health question. Adropin is not an approved drug. Where doses appear below, they are described only as they were reported in the cited source.

Where it is expressed

Human tissue expression work has placed adropin in a broader biological context than "liver peptide". A 2025 analysis reported that adropin expression in human tissues reflected circadian, lipoprotein and mitochondrial processes, linking ENHO transcript patterns to those coordinated programmes rather than to a single organ system (PMID 40578684). That framing matters for anyone meeting the term: adropin appears where energy partitioning is being coordinated across the day.

Pancreatic tissue has also been examined. Researchers reported that adropin was expressed in pancreatic islet cells and that it reduced glucagon release in the setting of diabetes mellitus, identifying an islet-level site of action in addition to the liver and vasculature emphasis of earlier work (PMID 39337311).

Summary of reported sites and signals

Cardiac and metabolic findings

The most developed strand of adropin research concerns the heart. A 2019 study reported that adropin regulated cardiac energy metabolism and improved cardiac function and efficiency, framing the peptide as a modifier of myocardial substrate selection rather than a direct inotrope (PMID 31202835).

That theme was extended into heart failure with preserved ejection fraction (HFpEF). Researchers reported that adropin protected against cardiac remodeling and metabolic dysfunction in a mouse model of HFpEF, first in a preprint (PMID 40654632) and subsequently in a peer-reviewed report in a male mouse HFpEF model (PMID 42275197). Because HFpEF is a syndrome with strong metabolic contributions, these reports are usually read alongside the cardiac energy-metabolism work rather than separately.

Injury models have added a signalling dimension. A 2022 study reported that adropin improved radiation-induced myocardial injury and implicated the VEGFR2/PI3K/Akt pathway in that effect (PMID 35923860). A separate rat study of polycystic ovarian syndrome reported that an adropin and tirzepatide combination mitigated cardiac metabolic aberrations, implicating the AKT/GSK3β/NF-κB/NLRP3 pathway (PMID 39795860). Across these papers the recurring mechanistic vocabulary is PI3K/Akt signalling, mitochondrial fuel handling and inflammasome-related inflammation.

Inflammation, fibrosis and reproductive tissue

Adropin has also been studied outside the cardiometabolic frame. In a colitis model, researchers reported that adropin deficiency worsened TNBS-induced colitis, an observation consistent with an anti-inflammatory or barrier-supporting role for endogenous adropin (PMID 37688913).

In fibrosis, a 2024 translational study reported attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis, positioning the peptide as a candidate modifier of the myofibroblast programme (PMID 38536934). Reproductive tissue has been examined too: a study in adult mice reported that adropin promoted testicular functions by modulating redox homeostasis (PMID 38878191).

How adropin is measured and studied

Two broad research designs dominate. The first is observational measurement of circulating adropin in patient groups, typically by immunoassay of serum. A 2022 study measured serum adropin levels in patients with rheumatoid arthritis, treating the peptide as a candidate biomarker rather than an intervention (PMID 35207457). The second is interventional animal and cell work, in which adropin is administered or its gene deleted, as in the colitis deficiency model (PMID 37688913) and the HFpEF mouse studies (PMID 42275197).

Biomarker studies come with a well-known interpretive caveat: a serum level that differs between groups does not establish direction of causation. Circadian variation is a particular concern for adropin given the reported link between its tissue expression and circadian processes (PMID 40578684), because sampling time can influence measured concentrations.

Adropin in Disease Contexts: What Studies Report

Not every reported association with adropin is favourable. A 2024 study reported that a high level of adropin promoted the progression of pancreatic ductal adenocarcinoma, describing the peptide as contributing to tumour behaviour in that model (PMID 37990897). That finding sits alongside the protective cardiac and anti-fibrotic reports and is a reminder that a pleiotropic metabolic peptide can have context-dependent consequences.

No verified clinical safety dataset in humans is summarised here, because the cited literature consists of animal interventions, cell work and observational serum measurements such as the rheumatoid arthritis study (PMID 35207457). Adverse-event profiles in people cannot be inferred from these designs.

Why the term comes up in peptide reading

Adropin appears in peptide discussions because it sits at the intersection of several topics that attract attention: energy metabolism, cardiac efficiency, fibrosis and glucose regulation. The combination study pairing adropin with tirzepatide in a rat PCOS model is one reason the name surfaces near incretin research (PMID 39795860). Readers encountering the term should note the evidence stage: the published work is preclinical and observational, with mechanistic pathways proposed but no approved human therapeutic. Materials described as research chemicals are not medicines, and nothing on this page describes human use.

References

• Adropin regulates cardiac energy metabolism and improves cardiac function and efficiency (Metabolism: Clinical and Experimental, 2019)
• Serum Adropin Levels in Patients with Rheumatoid Arthritis (Life, 2022)
• Adropin Improves Radiation-Induced Myocardial Injury via VEGFR2/PI3K/Akt Pathway (Oxidative Medicine and Cellular Longevity, 2022)
• Adropin deficiency worsens TNBS-induced colitis (International Immunopharmacology, 2023)
• High Level of Adropin Promotes the Progression of Pancreatic Ductal Adenocarcinoma (Current Cancer Drug Targets, 2024)
• Attenuation of fibroblast activation and fibrosis by adropin in systemic sclerosis (Science Translational Medicine, 2024)
• Adropin promotes testicular functions by modulating redox homeostasis in adult mouse (Endocrine, 2024)
• Adropin Is Expressed in Pancreatic Islet Cells and Reduces Glucagon Release in Diabetes Mellitus (International Journal of Molecular Sciences, 2024)
• Adropin/Tirzepatide Combination Mitigates Cardiac Metabolic Aberrations in a Rat Model of Polycystic Ovarian Syndrome (International Journal of Molecular Sciences, 2024)
• Adropin expression reflects circadian, lipoprotein, and mitochondrial processes in human tissues (Molecular Metabolism, 2025)
• Adropin protects against cardiac remodeling and metabolic dysfunction in a mouse model of HFpEF (bioRxiv, 2025)
• Adropin protects against cardiac remodeling and metabolic dysfunction in a male mouse HFpEF model (Clinical Science, 2026)